Recce Pharmaceuticals Ltd (ASX:RCE)
0.3250
-0.0150 (-4.41%)
Sep 22, 2026, 3:54 PM AEST
Recce Pharmaceuticals Revenue
In the fiscal year ending June 30, 2026, Recce Pharmaceuticals had annual revenue of 9.47M AUD with 26.06% growth. Recce Pharmaceuticals had revenue of 9.05M in the half year ending June 30, 2026, with 242.04% growth.
Revenue
9.47M
Revenue Growth
+26.06%
P/S Ratio
10.50
Revenue / Employee
n/a
Employees
n/a
Market Cap
99.38M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2026 | 9.47M | 1.96M | 26.06% |
| Jun 30, 2025 | 7.51M | 2.48M | 49.33% |
| Jun 30, 2024 | 5.03M | 663.14K | 15.19% |
| Jun 30, 2023 | 4.37M | 1.28M | 41.50% |
| Jun 30, 2022 | 3.08M | 1.45M | 88.41% |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Dimerix | 6.35M |
| Amplia Therapeutics | 4.79M |
| Alterity Therapeutics | 3.61M |
| Arovella Therapeutics | 3.50M |
| Prescient Therapeutics | 3.45M |
| Nyrada | 2.01M |
| Entropy Neurodynamics | 1.91M |
| Avecho Biotechnology | 737.30K |
Recce Pharmaceuticals News
- 20 days ago - Recce Pharmaceuticals Annual report: H2 2026 - Filings
- 21 days ago - Recce Pharmaceuticals Slides: Investor presentation - Filings
- 5 weeks ago - Recce in govt hospitals, illegal IVF route: How women gang ran child trafficking racket - The Times of India
- 7 weeks ago - Recce Pharmaceuticals Slides: Corporate presentation - Filings
- 2 months ago - Recce Pharmaceuticals Slides: Investor presentation - Filings
- 4 months ago - Recce Pharmaceuticals Slides: Corporate presentation - Filings
- 6 months ago - Recce Pharmaceuticals Transcript: Investor update - Transcripts
- 6 months ago - Recce Pharmaceuticals Quarterly report: H1 2026 - Filings